Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dapirolizumab pegol by UCB for Systemic Lupus Erythematosus: Likelihood of Approval
Dapirolizumab pegol is under clinical development by UCB and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...
Zilucoplan by UCB for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome): Likelihood of Approval
Zilucoplan is under clinical development by UCB and currently in Phase I for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated...
Zilucoplan by UCB for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Zilucoplan is under clinical development by UCB and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase...
Brivaracetam by UCB for Epilepsy: Likelihood of Approval
Brivaracetam is under clinical development by UCB and currently in Phase III for Epilepsy. According to GlobalData, Phase III drugs...
Bimekizumab by UCB for Psoriatic Arthritis: Likelihood of Approval
Bimekizumab is under clinical development by UCB and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs for...
Bimekizumab by UCB for Axial Spondyloarthritis: Likelihood of Approval
Bimekizumab is under clinical development by UCB and currently in Pre-Registration for Axial Spondyloarthritis. According to GlobalData, Pre-Registration drugs for...
Zilucoplan by UCB for Lupus Nephritis: Likelihood of Approval
Zilucoplan is under clinical development by UCB and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I...
Bimekizumab by UCB for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval
Bimekizumab is under clinical development by UCB and currently in Pre-Registration for Ankylosing Spondylitis (Bekhterev's Disease). According to GlobalData, Pre-Registration...
Bimekizumab by UCB for Hidradenitis Suppurativa: Likelihood of Approval
Bimekizumab is under clinical development by UCB and currently in Pre-Registration for Hidradenitis Suppurativa. According to GlobalData, Pre-Registration drugs for...
UCB-0022 by UCB for Parkinson's Disease: Likelihood of Approval
UCB-0022 is under clinical development by UCB and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase II...
UCB-7853 by UCB for Parkinson's Disease: Likelihood of Approval
UCB-7853 is under clinical development by UCB and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase I...
Rotigotine ER by UCB for Frontotemporal Dementia (FTD): Likelihood of Approval
Rotigotine ER is under clinical development by UCB and currently in Phase II for Frontotemporal Dementia (FTD). According to GlobalData,...